Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from CanSino Biologics, Inc. Class H ( (HK:6185) ) is now available.
CanSino Biologics has issued a forecast for 2025 indicating that revenue is expected to rise to between RMB1.04 billion and RMB1.08 billion, representing year-on-year growth of roughly 23% to 28%, driven largely by strong uptake of its Menhycia® MCV4 vaccine and enhanced commercialization efforts. The company expects to swing from a substantial loss in 2024 to a net profit attributable to shareholders of RMB24.5 million to RMB29.0 million in 2025, although it still anticipates a net loss after deducting non-recurring items, reflecting the significant impact of government grants and international funding on headline earnings; improved cost control, better coordination between production and sales, and higher gross margins underpin the improved profitability outlook and signal a strengthening operational and competitive position in China’s vaccine market.
The most recent analyst rating on (HK:6185) stock is a Hold with a HK$38.00 price target. To see the full list of analyst forecasts on CanSino Biologics, Inc. Class H stock, see the HK:6185 Stock Forecast page.
More about CanSino Biologics, Inc. Class H
CanSino Biologics Inc. is a China-based biopharmaceutical company specializing in the research, development and commercialization of innovative vaccines. The group focuses on advancing novel vaccine products, such as its quadrivalent meningococcal conjugate vaccine Menhycia®, to capture growth opportunities in the domestic immunization market and support international expansion through collaborations and funded research programs.
Average Trading Volume: 857,030
Technical Sentiment Signal: Sell
Current Market Cap: HK$15.19B
See more insights into 6185 stock on TipRanks’ Stock Analysis page.